Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EPS (Weighted Average and Diluted) (2020 - 2025)

Intellia Therapeutics (NTLA) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.81 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 36.22% to -$0.81 in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.81, a 27.43% increase, with the full-year FY2025 number at -$3.81, up 27.43% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.81 for Q4 2025 at Intellia Therapeutics, up from -$0.92 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.81 in Q4 2025 to a low of -$1.96 in Q1 2022.
  • A 5-year average of -$1.25 and a median of -$1.27 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 53.61% in 2022, then skyrocketed 40.31% in 2023.
  • Intellia Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.11 in 2021, then dropped by 24.32% to -$1.38 in 2022, then fell by 5.8% to -$1.46 in 2023, then increased by 13.01% to -$1.27 in 2024, then skyrocketed by 36.22% to -$0.81 in 2025.
  • Per Business Quant, the three most recent readings for NTLA's EPS (Weighted Average and Diluted) are -$0.81 (Q4 2025), -$0.92 (Q3 2025), and -$0.98 (Q2 2025).